Skip to main content
Top
Published in: Familial Cancer 3/2010

Open Access 01-09-2010

Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer

Authors: Karijn P. M. Suijkerbuijk, Elsken van der Wall, Helen Meijrink, Xiaojuan Pan, Inne H. M. Borel Rinkes, Margreet G. E. M. Ausems, Paul J. van Diest

Published in: Familial Cancer | Issue 3/2010

Login to get access

Abstract

The high rate of interval malignancies urges for new screening methods for women at high risk for breast cancer. Nipple aspiration provides direct access to the breast tissue and its DNA, and therefore is a likely candidate, but clinical applications have been limited by the failure to obtain nipple aspiration fluid from most women. We performed oxytocin-assisted nipple aspiration in 90 women at increased risk for breast cancer based on family history or genetic test results (n = 63) and/or previous breast cancer (n = 34). Nipple fluid was obtained from 81/90 women (90%) and bilaterally in 77%. Mean discomfort rating was 0.6 (on a 0–10 scale), which was significantly lower than for mammography or MRI. These findings suggest that a new tool for biomarker detection in oxytocin-assisted nipple fluid of women at high risk for breast cancer is at hand.
Literature
2.
go back to reference King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646CrossRefPubMed King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646CrossRefPubMed
3.
go back to reference Brekelmans CT, Seynaeve C, Bartels CC et al (2001) Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19(4):924–930PubMed Brekelmans CT, Seynaeve C, Bartels CC et al (2001) Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19(4):924–930PubMed
4.
go back to reference Suijkerbuijk KP, van der Wall E, Vooijs M, van Diest PJ (2008) Molecular analysis of nipple fluid for breast cancer screening. Pathobiology 75(2):149–152CrossRefPubMed Suijkerbuijk KP, van der Wall E, Vooijs M, van Diest PJ (2008) Molecular analysis of nipple fluid for breast cancer screening. Pathobiology 75(2):149–152CrossRefPubMed
5.
go back to reference Fabian CJ, Kimler BF, Mayo MS, Khan SA (2005) Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 12(2):185–213CrossRefPubMed Fabian CJ, Kimler BF, Mayo MS, Khan SA (2005) Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 12(2):185–213CrossRefPubMed
6.
go back to reference Wrensch MR, Petrakis NL, Gruenke LD et al (1990) Factors associated with obtaining nipple aspirate fluid: analysis of 1428 women and literature review. Breast Cancer Res Treat 15(1):39–51CrossRefPubMed Wrensch MR, Petrakis NL, Gruenke LD et al (1990) Factors associated with obtaining nipple aspirate fluid: analysis of 1428 women and literature review. Breast Cancer Res Treat 15(1):39–51CrossRefPubMed
7.
go back to reference Suijkerbuijk KP, van der Wall E, van Diest PJ (2007) Oxytocin: bringing magic into nipple aspiration. Ann Oncol 18(10):1743–1744CrossRefPubMed Suijkerbuijk KP, van der Wall E, van Diest PJ (2007) Oxytocin: bringing magic into nipple aspiration. Ann Oncol 18(10):1743–1744CrossRefPubMed
8.
go back to reference Fackler MJ, McVeigh M, Mehrotra J et al (2004) Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 64(13):4442–4452CrossRefPubMed Fackler MJ, McVeigh M, Mehrotra J et al (2004) Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 64(13):4442–4452CrossRefPubMed
9.
go back to reference Loud JT, Thiebaut ACM, Abati AD et al (2009) Ductal lavage in women from BRCA1/2 families: is there a future for ductal lavage in women at increased genetic risk of breast cancer? Cancer Epidemiol Biomarkers Prev 18(4):1243–1251CrossRefPubMed Loud JT, Thiebaut ACM, Abati AD et al (2009) Ductal lavage in women from BRCA1/2 families: is there a future for ductal lavage in women at increased genetic risk of breast cancer? Cancer Epidemiol Biomarkers Prev 18(4):1243–1251CrossRefPubMed
10.
go back to reference Fackler MJ, Malone K, Zhang Z et al (2006) Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 12(11):3306–3310CrossRefPubMed Fackler MJ, Malone K, Zhang Z et al (2006) Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 12(11):3306–3310CrossRefPubMed
11.
go back to reference Dooley WC, Ljung BM, Veronesi U et al (2001) Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 93(21):1624–1632CrossRefPubMed Dooley WC, Ljung BM, Veronesi U et al (2001) Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 93(21):1624–1632CrossRefPubMed
Metadata
Title
Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer
Authors
Karijn P. M. Suijkerbuijk
Elsken van der Wall
Helen Meijrink
Xiaojuan Pan
Inne H. M. Borel Rinkes
Margreet G. E. M. Ausems
Paul J. van Diest
Publication date
01-09-2010
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2010
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9344-7

Other articles of this Issue 3/2010

Familial Cancer 3/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine